ci 924 has been researched along with Hyperlipoproteinemia Type IV in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corder, CN; Kloer, HU; Price, MD | 1 |
1 trial(s) available for ci 924 and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
Topics: Apolipoproteins; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged | 1989 |